4 ms·
> Also what would be the bad outcomes here? If those drugs end up not being safe (that is prevented by the requirement to not withhold safety data), or being ef
by ceejayoz 10d ago
> Also what would be the bad outcomes here? If those drugs end up not being safe (that is prevented by the requirement to not withhold safety data), or being effective?
Barring a time machine, safety data reporting is gonna lag at least some of the bad outcomes.
- niklas_anzinger 10d agoThat is the same with all post-market monitoring for drugs. And maybe we can do better because more nimble/startup approach in a small state
- ceejayoz 10d agoIsn't this pre-market, though?
- niklas_anzinger 10d agoRelative to the federal approval it's pre-market. In Montana, if your treatment is approved by a review board it's in market
- estearum 9d agoBut there are, obviously, proportionally way fewer bad outcomes created by drugs that pass Phases 2 and 3 than those that only pass Phase 1. The steepness of that attrition is literally the entire value prop of the law to begin with.